Bicycle Therapeutics Ltd (BCYC)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $236.22M
Last updated: Nov 17, 2026 at 11:04 AM ET
Bicycle Therapeutics Ltd (BCYC) Stock Forecast
Analysts expect Bicycle Therapeutics (BCYC) to earn -$2.26 per share in the fiscal year ending Dec 31, 2026, on revenue of $38.04M. Of 9 analysts, 6 rate the stock Buy or Strong Buy, 3 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 9 ratings average 2.11, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 67% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 22.2% |
| Buy | 4 | 44.4% |
| Hold | 3 | 33.3% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 9
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates fall 81.7%.
- Fiscal year ending Dec 31, 2026
- -$2.26
- EPS consensus, revenue $38.04M
- Fiscal year ending Dec 31, 2027
- -$2.33
- EPS consensus, revenue $6.95M
- Fiscal year ending Dec 31, 2028
- -$2.17
- EPS consensus, revenue $27.21M
- Next report
- Mar 15, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$2.26 | -$2.45 to -$2.04 | 8 | $38.04M | $35.77M to $50.00M | 9 |
| Dec 31, 2027 | -$2.33 | -$2.94 to -$1.48 | 9 | $6.95M | N/A | 9 |
| Dec 31, 2028 | -$2.17 | -$3.06 to -$1.29 | 6 | $27.21M | $26.76M to $27.65M | 9 |
Quarterly Estimates
The EPS consensus falls from -$0.44 for the quarter ending Dec 31, 2026 to -$0.61 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.44 | -$0.64 to $0.33 | 12 | $1.86M | $539000 to $6.30M | 11 |
| Mar 31, 2027 | -$0.61 | -$0.65 to -$0.55 | 3 | $1.07M | N/A | 4 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 3 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 1 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$2.61.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$2.26 | -$2.26 | -$2.45 | -$2.45 | -$2.61 | N/A |
| Fiscal year ending Dec 31, 2027 | -$2.33 | -$2.32 | -$2.22 | -$2.22 | -$2.22 | N/A |
| Quarter ending Mar 31, 2027 | -$0.61 | -$0.59 | -$0.59 | -$0.59 | -$0.59 | N/A |
Frequently Asked Questions About BCYC
What is the BCYC stock forecast?
Consensus analyst estimates put Bicycle Therapeutics's EPS at -$2.26 for the fiscal year ending Dec 31, 2026, on revenue of $38.04M. The consensus rating from 9 analysts is Buy.
How do analysts rate BCYC stock?
Of 9 analysts covering Bicycle Therapeutics, 2 rate it Strong Buy, 4 Buy, 3 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from BCYC next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.26, with estimates from -$2.45 to -$2.04 from 8 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.33, with estimates from -$2.94 to -$1.48 from 9 analysts.
What revenue do analysts expect from Bicycle Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $38.04M, with estimates from $35.77M to $50.00M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $6.95M.
How many analysts cover BCYC?
9 analysts rate Bicycle Therapeutics stock, and 8 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
BCYC pages: Overview, Earnings, Forecast, Financials, Competitors